Gaurav Shah Rocket Pharmaceuticals, Inc. (RCKT) insider trading activity

Gaurav Shah is CEO of ROCKET PHARMACEUTICALS, INC.. Currently has a direct ownership of 707,328 shares of RCKT, which is worth approximately $8.26 Million. The most recent transaction as insider was on Nov 21, 2024, when has been sold 11,091 shares (Common Stock) at a price of $13.05 per share, resulting in proceeds of $144,737. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 707K

1.54% 3M change

32.75% 12M change

Total Value Held $8.26 Million

Gaurav Shah Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 21 2024	SELL Open market or private sale	$144,737 $13.05 p/Share	11,091 Reduced 1.54%	707,328 Common Stock
Aug 16 2024	SELL Open market or private sale	$178,525 $18.5 p/Share	9,650 Reduced 1.33%	718,419 Common Stock
May 16 2024	SELL Open market or private sale	$228,596 $23.35 p/Share	9,790 Reduced 1.33%	728,069 Common Stock
May 14 2024	BUY Exercise of conversion of derivative security	-	17,662 Added 2.66%	646,134 Common Stock
Feb 16 2024	SELL Open market or private sale	$604,916 $29.84 p/Share	20,272 Reduced 3.53%	554,762 Common Stock
Feb 16 2024	BUY Grant, award, or other acquisition	-	66,577 Added 9.68%	621,339 Common Stock
Feb 14 2024	SELL Exercise of conversion of derivative security	-	46,828 Reduced 7.53%	575,034 Common Stock
Nov 14 2023	SELL Exercise of conversion of derivative security	-	7,979 Reduced 1.48%	532,833 Common Stock
Aug 17 2023	SELL Open market or private sale	$73,745 $15.47 p/Share	4,767 Reduced 0.9%	524,854 Common Stock
Aug 14 2023	BUY Exercise of conversion of derivative security	-	7,979 Added 1.48%	529,621 Common Stock
May 17 2023	SELL Open market or private sale	$88,128 $21.38 p/Share	4,122 Reduced 0.78%	521,642 Common Stock
May 14 2023	BUY Exercise of conversion of derivative security	-	7,979 Added 1.49%	525,764 Common Stock
Feb 17 2023	SELL Open market or private sale	$232,417 $19.06 p/Share	12,194 Reduced 2.22%	536,885 Common Stock
Feb 14 2023	BUY Other acquisition or disposition	-	67,785 Added 8.41%	737,859 Common Stock
Feb 14 2022	BUY Other acquisition or disposition	-	23,940 Added 3.45%	670,074 Common Stock
Feb 07 2022	BUY Open market or private purchase	$381,480 $17.34 p/Share	22,000 Added 4.08%	517,639 Common Stock
Apr 01 2021	SELL Payment of exercise price or tax liability	$1,030,693 $46.29 p/Share	22,266 Reduced 4.3%	495,639 Common Stock
Mar 31 2021	SELL Payment of exercise price or tax liability	$344,228 $45.94 p/Share	7,493 Reduced 1.43%	517,905 Common Stock
Mar 31 2021	SELL Payment of exercise price or tax liability	$3,927,391 $44.96 p/Share	87,353 Reduced 14.26%	525,398 Common Stock
Mar 31 2021	BUY Exercise of conversion of derivative security	$128,237 $1.69 p/Share	75,880 Added 11.02%	612,751 Common Stock
Mar 30 2021	SELL Payment of exercise price or tax liability	$3,710,362 $43.2 p/Share	85,888 Reduced 13.79%	536,871 Common Stock

Also insider at

TALS

Talaris Therapeutics, Inc. Healthcare

Director

Gaurav Shah

CEO

Cranbury, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RCKT shares.

Notify only if

Value

Insider Trading

Get notified when an Rocket Pharmaceuticals, Inc. insider buys or sells RCKT shares.

Notify only if

Operation

Value

Type

News

Receive news related to ROCKET PHARMACEUTICALS, INC.

Track Activities on RCKT

Account